ANALISIS BIAYA DAN RASIONALITAS TERAPI PARU OBSTRUKTIF KRONIK DI RSU ANWAR MEDIKA SIDOARJO

Authors

  • Amelia Lorensia Uniersitas Surabaya
  • Marthy Meliana Jalmav Fakultas Farmasi, Universitas Anwar Medika, Sidoarjo, Indonesia
  • Yosy Athaya Yorasaki Fakultas Farmasi, Universitas Surabaya, Surabaya, Indonesia
  • I Nyoman Dodi Saputra Fakultas Farmasi, Universitas Surabaya, Surabaya, Indonesia
  • Putu Aprilya Gitaputri Fakultas Farmasi, Universitas Surabaya, Surabaya, Indonesia

DOI:

https://doi.org/10.36387/jiis.v9i1.1716

Keywords:

COPD, real costs, INA-CBGs rates, drug-related problems

Abstract

COPD is the main cause of death, and is currently the fifth cause of death in the world. COPD patients experience decreased capacity for quality of life, physical disability and increased costs of living. In COPD patients, the use of more than one drug therapy and long-term use can carry the risk of drug-related problems. The aim is to analyze the costs and rationality of treating COPD exacerbations. The research design was retrospective to determine the costs and description of therapy for COPD patients at RSU Anwar Medika Sidoarjo. The variables are real costs, INA-CBGs rates, severity and treatment therapy. The research sample was inpatients with BPJS insurance who were diagnosed with COPD attacks at RSU Anwar Medika Sidoarjo for January 2019-December 2021, using the total sampling method. The data collection by observing research materials including medical records. Data analysis is descriptive for data analysis and the incidence of drug-related problems (MTO), and the Mann-Whitney test to determine significant differences between real hospital costs and INA CBG'S inpatient rates. The number of respondents involved was 81 people. The highest components of direct costs incurred by COPD patients during hospitalization are hotel room costs and the cost of consumable medical materials. There was no difference in real costs compared to the rates INA-CBG's (p=0.158). The total incidence of MTO that occurred was 83 cases consisting of inappropriate drug selection (19.27%), drugs without indications (66.26%), inappropriate drug combinations (4.81%), indications without drugs (2 .40%), too many drugs for  same indication (7.22%).

References

Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;61(4):2300239.

Alaydrus S. Cost Analysis of Chronic Obstructive Pulmonary Disease Treatment of Inpatients in District of. Jurnal Ilmiah Farmasi Farmasyifa. 2020;3(1):51–61.

Baneen U, Naseem S. Correlation of severity of chronic obstructive pulmonary disease with serum vitamin-D level. J Family Med Prim Care. 2019;8(7):2268-77. doi: 10.4103/jfmpc.jfmpc_404_19. PMID: 31463241; PMCID: PMC6691443.

Brandsma CA, Van den Berge M, Hackett TL, Brusselle G, Timens W. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J Pathol. 2020 Apr;250(5):624-635.

Brill SE, Wedzicha JA. Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:1241-52.

Cheng SL, Lin CH. COPD Guidelines in the Asia-Pacific Regions: Similarities and Differences. Diagnostics (Basel). 2021;11(7):1153.

Choi JY, Rhee CK. Diagnosis and Treatment of Early Chronic Obstructive Lung Disease (COPD). J Clin Med. 2020;9(11):3426.

Deawjaroen K, Sillabutra J, Poolsup N, Stewart D, Suksomboon N. Characteristics of drug-related problems and pharmacist's interventions in hospitalized patients in Thailand: a prospective observational study. Sci Rep. 2022;12(1):17107.

Fragoso CA. Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in Aging Populations. COPD. 2016;13(2):125-9.

Global Initiative for Chronic Obstructive Lung Disease. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2022 Report. In Chinese General Practice. 2022;25(11):1-165.

Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:439-60.

Iradatillah S. Identifikasi Drug Related Problems Pada Pasien Penyakit Paru Obstruktif Kronik Dengan Penyakit Penyerta Di Instalasi Rawat Inap RSUP H. Adam Malik Medan. Universitas Sumatera Utara. 2020;1–177.

Kirkland SW, Vandenberghe C, Voaklander B, Nikel T, Campbell S, Rowe BH. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev. 2017;1(1):CD001284.

Kopsaftis ZA, Sulaiman NS, Mountain OD, Carson-Chahhoud KV, Phillips PA, Smith BJ. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review. Syst Rev. 2018;7(1):213.

Lakiang T, Nair NS, Ramaswamy A, Singhal U. Economic impact of chronic obstructive pulmonary disease: A cross-sectional study at teaching hospital in South India. J Family Med Prim Care. 2018;7(5):1002-6.

Li LC, Han YY, Zhang ZH, Zhou WC, Fang HM, Qu J, Kan LD. Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management. Drug Des Devel Ther. 2021;15:111-24.

Lorensia A. Prinsip Dasar dan Aplikasi dalam Pelayanan Kefarmasian: Buku Ajar Farmakoekonomi. Direktorat Penerbitan dan Publikasi Ilmiah Universitas Surabaya; 2020.

Lorensia A, Fatmala D. Analisis Masalah Terkait Obat Pada Pengobatan Asma Rawat Jalan. Jurnal Ilmiah Manuntung. 2021;7(1):126-37.

Monica RD, Mawar F, Suryati Y, Pujilestari I, Rohmayani D, Hendrati A. Analisis Perbedaan Tarif Riil Rumah Sakit Dengan Tarif INA-CBG’s Berdasarkan Kelengkapan Medis Pasien Rawat Inap Pada Kasus Persalinan Sectio Caesarea Guna Pengendalian Biaya Rumah Sakit TNI AU Dr. M. Salamun Bandung. Jmiki. 2021;9(1):90–96.

Rajkumar SV. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71.

Rodrigues SO, Cunha CMCD, Soares GMV, Silva PL, Silva AR, Gonçalves-de-Albuquerque CF. Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease. Pharmaceuticals (Basel). 2021;14(10):979.

Rosenwasser Y, Berger I, Loewy ZG. Therapeutic Approaches for Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. Pathogens. 2022;11(12):1513.

Rossi A, Butorac-Petanjek B, Chilosi M, Cosío BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies. Int J Chron Obstruct Pulmon Dis. 2017;12:2593-2610.

Santoso A, Sulistyaningrum IH, Rosyid A, Cahyono EB, Wirastuti K, Riyanto B. Perbandingan biaya riil dengan tarif INA-CBG’S penyakit kanker payudara pada era jaminan kesehatan nasional. Jurnal Farmasi Sains dan Praktis (JFSP). 2020;6(1):60-6.

Satria MA, Andrajati R, Supardi S. The Translation Process of Pharmaceutical Care Network Europe v9.00 to Bahasa Indonesia: An Instrument to Detect Drug-Related Problem. Malays J Med Sci. 2022;29(3):133-44.

Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Front Pharmacol. 2020;11:420.

Walters JA, Tan DJ, White CJ, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;3(3):CD006897.

Wang Y, Li X, Jia D, Lin B, Fu B, Qi B, Zhang Z. Exploring polypharmacy burden among elderly patients with chronic diseases in Chinese community: a cross-sectional study. BMC Geriatr. 2021;21(1):308.

Yawn BP, Mintz ML, Doherty DE. GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289-99.

Published

2024-03-31

Issue

Section

Article

How to Cite

ANALISIS BIAYA DAN RASIONALITAS TERAPI PARU OBSTRUKTIF KRONIK DI RSU ANWAR MEDIKA SIDOARJO . (2024). Jurnal Ilmiah Ibnu Sina, 9(1), 144-159. https://doi.org/10.36387/jiis.v9i1.1716

Similar Articles

21-30 of 214

You may also start an advanced similarity search for this article.